Physician profile
Maria Marks
NPI 1437367182
$15,835.05
in general payments reported to CMS, 2019-2025
40 companies · $2,308 in 2025
The $2,308 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $1,555 · 2021: $1,809 · 2022: $2,222 · 2023: $3,164 · 2024: $2,714 · 2025: $2,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,106 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,105.77 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,165.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,462.48 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,195.29 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $891.21 | 2019-2025 | Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $871.35 | 2019-2025 | |
| Leo Pharma INC. | $856.18 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $781.31 | 2020-2025 | Dupixent, Libtayo |
| Allergan, INC. | $725.80 | 2019-2022 | |
| Incyte Corporation | $683.69 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $681.24 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $597.94 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $529.65 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Arcutis Biotherapeutics, INC. | $527.74 | 2023-2025 | Zoryve |
| Pfizer INC. | $506.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $418.93 | 2022-2024 | Sotyktu |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $367.87 | 2022-2024 | Vtama |
| Ucb, INC. | $355.32 | 2021-2025 | Bimzelx, Cimzia |
| Epi Health, LLC | $350.17 | 2019-2022 | |
| Janssen Biotech, INC. | $313.79 | 2020-2025 | Tremfya |
| Journey Medical Corporation | $213.56 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $164.63 | 2020-2021 | |
| Encore Dermatology INC. | $143.19 | 2019-2020 | |
| Amgen INC. | $128.35 | 2022-2025 | Otezla, Otezla |
| Almirall LLC | $120.27 | 2019-2021 | |
| Dermira, INC. | $108.19 | 2019-2020 | |
| Biofrontera INC. | $81.90 | 2019-2025 | |
| Aclaris Therapeutics, INC. | $75.84 | 2019 | |
| Organon LLC | $75.64 | 2024-2025 | Hadlima |
| Genentech USA, INC. | $70.84 | 2019-2022 | |
| Mission Pharmacal Company | $69.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.87 | 2023-2024 | Spevigo |
| Dusa Pharmaceuticals, INC. | $54.17 | 2019 | |
| Verrica Pharmaceuticals INC. | $38.08 | 2023-2024 | Ycanth |
| Botanix Sb INC | $35.50 | 2025 | Sofdra |
| Kerecis Limited | $35.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Revance Therapeutics, INC. | $20.61 | 2024 | Daxxify |
| Prugen, INC. Pharmaceuticals | $15.73 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $13.72 | 2019 | |
| Nabriva Therapeutics, Plc | $13.43 | 2022 | |
| Celgene Corporation | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.